HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (Nasdaq:ARDM) ("Aradigm" or the "Company") today
announced that it received notice from The NASDAQ Capital Market
("NASDAQ") indicating that the Company has regained compliance under
NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ
Capital Market as the Company's market value of listed securities has
been $35 million or greater for the last 10 consecutive business days
from September 22 through October 5, 2017. Accordingly, Aradigm is in
compliance with the applicable listing standards, its common stock will
continue to be listed on The NASDAQ Capital Market and NASDAQ considers
the matter closed.
Aradigm had previously been notified by NASDAQ on April 4, 2017 that it
did not comply with the minimum $2.5 million stockholders' equity, or
$35 million market value of listed securities, or $500,000 of net income
from continuing operations requirements for The NASDAQ Capital Market
set forth in Listing Rules 5550(b)(1), or 5550(b)(2), or 5550(b)(3),
respectively.
About Aradigm
Aradigm is an emerging specialty pharmaceutical company focused on the
development and commercialization of drugs for the prevention and
treatment of severe respiratory diseases. Aradigm has completed two
Phase 3 clinical trials with Linhaliqâ„¢, an investigational proprietary
formulation of ciprofloxacin for inhalation, for the treatment of NCFBE
and submitted a New Drug Application to the FDA for this indication. The
PDUFA (Prescription Drug User Fee Act) goal date for completion of the
FDA review of the Linhaliq NDA is January 26, 2018. Aradigm's inhaled
ciprofloxacin formulations, including Linhaliq, are also product
candidates for treatment of patients with cystic fibrosis and
non-tuberculous mycobacteria, and for the prevention and treatment of
high threat and bioterrorism infections, such as inhaled tularemia,
pneumonic plague, melioidosis, Q fever and inhaled anthrax.
More information about Aradigm can be found at www.aradigm.com.
Aradigm and the Aradigm Logo are registered trademarks of Aradigm
Corporation.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171010005440/en/
Aradigm Corporation
Nancy Pecota, 510-265-8800
Chief Financial
Officer
Source: Aradigm Corporation
News Provided by Acquire Media